Navigation Links
Zysolin(TM) Pre-clinical Data Supports Once-a-day Dosing in Humans
Date:6/18/2009

    AlphaRx's inhaled Tobramycin nanoparticle formulation provides 300% more
    availability than standard free drug in lung tissue, as demonstrated in a
    recent animal pharmacokinetic study.

MARKHAM, ON, June 18 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX) is pleased to report a significant breakthrough in the development of Zysolin(TM), an inhaled Tobramycin nanoparticle formulation utilizing the company's proprietary drug delivery platform, and intended for the adjunctive treatment of Pseudomonas Aeruginosa Pneumonia in intubated and mechanically-ventilated patients (VAP).

In a recent pivotal animal PK (pharmacokinetic) study, Zysolin(TM) delivered 300% more drug to lung tissue than free drug, when utilizing the same delivery method. This data demonstrates that Zysolin(TM) provides superior lung tissue penetration and a release profile which supports once-a-day human dosing frequency.

The study data will be presented, by invitation, to the upcoming July meeting of the Controlled Release Society Conference in Copenhagen, Denmark.

Dr. Michael Weisspapir, MD, PhD, Chief Medical Scientist of AlphaRx commented, "As a result of this pre-clinical data, we anticipate that the demonstrated superiority over free drug availability will result in higher drug concentrations in lung tissue, enhancing clinical efficacy for VAP patients in vivo."

About Zysolin(TM)

Zysolin(TM) is a Tobramycin compound, encapsulated in AlphaRx's Nano Drug Delivery Platform, intended for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients. Zysolin(TM) improves the intracellular activity of Tobramycin - in layman's term, increasing the drug concentration of Tobramycin inside human macrophages, thus improving its antibacterial activity against intracellular Klebsiella, Pseudomondas aeruginosa and Staphylococcus bacterial strains in pneumonia patients. The active ingredient in Zysolin(TM), Tobramycin, has a long-standing and proven clinical treatment record. Delivered by inhalation, using proprietary nanotechnology developed by AlphaRx, the company believes Zysolin(TM) will have an attractive safety, tolerability and efficacy profile when compared to injectible Tobramycin.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PointCross Releases Pre-Clinical Study Lifecycle and Data Management Suite (PC-LDM(TM)) For Multi-Party Environments
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
4. Bioniche Presents Pre-Clinical Research at Two International Conferences
5. Senesco Announces Results of Pre-Clinical Efficacy, Toxicology and Dose Ranging Studies for Multiple Myeloma Therapeutic Candidate
6. Drug inhibits neuroblastoma blood supply in pre-clinical tests
7. Drug therapy reduces neuroblastoma tumor growth in pre-clinical investigation
8. HealthFitness CEO Supports Move Toward Cultural Shift, and Science-Based Health Management Programming
9. Diageo Supports First Ever National We Dont Serve Teens Week
10. The Prem Rawat Foundation Supports Disaster-Relief Efforts in Mozambique
11. Discovery supports theory of Alzheimers disease as form of diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald E. Hawkins, vice ... appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new ... 10. Dr. Bell comes to Liberty from the Ohio University Heritage College of ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... it is so critically important that we all are aware of our options ... Mediaplanet is proud to announce the launch of its newest edition of "Vision ...
(Date:2/24/2017)... Aliso Viejo, CA (PRWEB) , ... February 24, 2017 , ... ... within Final Cut Pro X . Users have total control over position, rotation, ... amount, and more all within Final Cut Pro X. , With ProGlass Prism users ...
(Date:2/24/2017)... ... 24, 2017 , ... The International Association of Eating Disorders Professionals (iaedp) announces ... See” body image mannequin art competition. Selected from 15 submissions from around the nation, ... at the 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... services, which specializes in thought leadership , media relations, social media, content ... services that will be powered through Act-On, an intuitive marketing automation platform. , ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Urinary Incontinence ... What are the key drugs marketed for Urinary Incontinence ...
(Date:2/23/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device company ... the urology market, will release financial results for the ... before the market open on Thursday, March 9, 2017. ... call and webcast to discuss its financial results the ... a.m. Eastern Time (10:00 a.m. Central Time). Darin ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
Breaking Medicine Technology: